Partnerships - Mediwound

Together We Can Reach Any Patient Anywhere

At MediWound, our mission is to make NexoBrid accessible to burn patients worldwide. We are making significant strides by partnering with leaders across diverse geographic regions, expanding our global footprint, and working collectively to establish NexoBrid as the new standard in burn care, thereby improving patients’ well-being and quality of life.

Our efforts to commercialize NexoBrid are actively supported by global partnerships, with our presence currently extending to over 40 countries. We are committed to accelerating our progress, recognizing that success is driven by people. Exceptional individuals form the foundation of exceptional partnerships. By integrating our innovative technology and dedicated team with our partners’ local marketing expertise and sales acumen, we are poised to elevate the standard of care for patients on a global scale.

Moreover, we have recently entered into a strategic collaboration with Mölnlycke Health Care, a global leader in wound care solutions. This partnership will further strengthen our strategic plans for EscharEx, creating substantial long-term value for our stakeholders and enhancing the standard of care for patients.

To advance our mission, we seek collaborations and partnerships that amplify our impact. If you're interested in partnering with us, reach out. Together, we can create a brighter future.

Governmental support

We are proud of our strategic collaboration in the U.S with the Advanced Biomedical, Research and Development Authority (BARDA), supporting the development and authorization of NexoBrid in the U.S, as well as procurement of NexoBrid for the U.S national emergency stockpile. We are also delighted to be in partnership with the U.S. Department of Defense to develop NexoBrid as a non-surgical solution for treating burns in field conditions.

Additionally, the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded us continued funding for the development of NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army.

Private Sector

We have partnered with Vericel Collaboration (Nasdaq: VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, to market and sell NexoBrid across North America. This agreement grants Vericel the rights to distribute NexoBrid to 140 burn centers across the United States, ensuring that patients receive cutting-edge treatment for severe burns.

Additionally, we entered into a strategic collaboration agreement with Mölnlycke Health Care, a world-leading MedTech company specializing in wound care and surgical solutions. This partnership is designed to strengthen our strategic plans for EscharEx.

These collaborations reflect our commitment to leveraging strategic partnerships to enhance our product offerings and expand our reach in the medical and healthcare markets.

$ 100M

$ 125M

$ 15M

$ 15M

We believe in empowering our distributors, recognizing the crucial role they play in delivering NexoBrid to burn patients worldwide.

We employ a comprehensive global strategy for NexoBrid's commercialization, using multiple sales channels. Our approach includes a dedicated European sales force, local sales representatives, and partnerships with distributors across the EU and Asia, ensuring NexoBrid's broad availability and accessibility to burn patients.